

Tian-Shu Liu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6513221/publications.pdf>

Version: 2024-02-01

79
papers

3,209
citations

361045

20
h-index

174990

52
g-index

86
all docs

86
docs citations

86
times ranked

4293
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition). <i>Liver Cancer</i> , 2018, 7, 235-260.	4.2	426
2	The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. <i>Cancer Communications</i> , 2019, 39, 1-31.	3.7	418
3	The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. <i>Cancer Communications</i> , 2021, 41, 747-795.	3.7	323
4	Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 2486.	3.8	202
5	LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study. <i>Annals of Oncology</i> , 2020, 31, S1191.	0.6	162
6	Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 350-358.	0.8	160
7	Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With <i>RAS</i> Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 3031-3039.	0.8	159
8	Use of radiation with or without WR-2721 in advanced rectal cancer. <i>Cancer</i> , 1992, 69, 2820-2825.	2.0	127
9	HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 2558-2567.	0.8	98
10	HnRNPR-CCNB1/CENPF axis contributes to gastric cancer proliferation and metastasis. <i>Aging</i> , 2019, 11, 7473-7491.	1.4	86
11	Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial. <i>BMC Cancer</i> , 2016, 16, 68.	1.1	82
12	c-Met as a Prognostic Marker in Gastric Cancer: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2013, 8, e79137.	1.1	68
13	Right- and left-sided colorectal cancers respond differently to cetuximab. <i>Chinese Journal of Cancer</i> , 2015, 34, 384-93.	4.9	63
14	Inhibition of STAT3 signaling pathway by ursolic acid suppresses growth of hepatocellular carcinoma. <i>International Journal of Oncology</i> , 2017, 51, 555-562.	1.4	49
15	STAT3 as a potential therapeutic target in ALDH+ and CD44+/CD24+ stem cell-like pancreatic cancer cells. <i>International Journal of Oncology</i> , 2016, 49, 2265-2274.	1.4	47
16	Small but Heavy Role: MicroRNAs in Hepatocellular Carcinoma Progression. <i>BioMed Research International</i> , 2018, 2018, 1-9.	0.9	31
17	The prognostic value of KRAS mutation by cell-free DNA in cancer patients: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2017, 12, e0182562.	1.1	26
18	Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia. <i>ESMO Open</i> , 2022, 7, 100341.	2.0	25

#	ARTICLE	IF	CITATIONS
19	Inhibition of IL-6/STAT3 signaling in human cancer cells using Evista. <i>Biochemical and Biophysical Research Communications</i> , 2017, 491, 159-165.	1.0	24
20	Bazedoxifene exhibits anti-inflammation and anti-atherosclerotic effects via inhibition of IL-6/IL-6R/STAT3 signaling. <i>European Journal of Pharmacology</i> , 2021, 893, 173822.	1.7	22
21	K-Ras mutation detection in liquid biopsy and tumor tissue as prognostic biomarker in patients with pancreatic cancer: a systematic review with meta-analysis. <i>Medical Oncology</i> , 2016, 33, 61.	1.2	21
22	Predictive factors of trastuzumab-based chemotherapy in HER2 positive advanced gastric cancer: a single-center prospective observational study. <i>Clinical and Translational Oncology</i> , 2018, 20, 695-702.	1.2	21
23	Hereditary Nonpolyposis Colorectal Cancer and Cancer Syndromes: Recent Basic and Clinical Discoveries. <i>Journal of Oncology</i> , 2018, 2018, 1-11.	0.6	21
24	Ophthalmic manifestations in a Chinese family with familial amyloid polyneuropathy due to a TTR Gly83Arg mutation. <i>Eye</i> , 2014, 28, 26-33.	1.1	20
25	Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1501-1510.	1.4	20
26	Oxaliplatin plus Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma in Combination with D2 Gastrectomy: NEO-CLASSIC Study. <i>Oncologist</i> , 2019, 24, 1311-e989.	1.9	20
27	Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis. <i>BMC Cancer</i> , 2018, 18, 702.	1.1	19
28	Development and validation of a new tumor-based gene signature predicting prognosis of HBV/HCV-included resected hepatocellular carcinoma patients. <i>Journal of Translational Medicine</i> , 2019, 17, 203.	1.8	18
29	Issues in the management of nasopharyngeal carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 1999, 31, 55-69.	2.0	17
30	Ursolic acid prevents angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E-knockout mice. <i>Atherosclerosis</i> , 2018, 271, 128-135.	0.4	17
31	Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients. <i>BMC Cancer</i> , 2020, 20, 1006.	1.1	17
32	Reduction in Peripheral CD19+CD24 ^{hi} CD27 ⁺ B Cell Frequency Predicts Favourable Clinical Course in XELOX-Treated Patients with Advanced Gastric Cancer. <i>Cellular Physiology and Biochemistry</i> , 2017, 41, 2045-2052.	1.1	16
33	Effect of Immune Checkpoint Inhibitors Plus Chemotherapy on Advanced Gastric Cancer Patients with Elevated Serum AFP or Hepatoid Adenocarcinoma. <i>Cancer Management and Research</i> , 2020, Volume 12, 11113-11119.	0.9	16
34	Raloxifene inhibits IL-6/STAT3 signaling pathway and protects against high-fat-induced atherosclerosis in ApoE ^{-/-} mice. <i>Life Sciences</i> , 2020, 261, 118304.	2.0	15
35	Inhibition of Interleukin-6/glycoprotein 130 signalling by Bazedoxifene ameliorates cardiac remodelling in pressure overload mice. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 4748-4761.	1.6	15
36	Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial. <i>BMC Medicine</i> , 2022, 20, 107.	2.3	15

#	ARTICLE	IF	CITATIONS
37	A point mutation of zebrafish c-cbl gene in the ring finger domain produces a phenotype mimicking human myeloproliferative disease. <i>Leukemia</i> , 2015, 29, 2355-2365.	3.3	14
38	Expert consensus on maintenance treatment for metastatic colorectal cancer in China. <i>Chinese Journal of Cancer</i> , 2016, 35, 13.	4.9	14
39	Platelet-to-lymphocyte ratio and lymphocyte-to-white blood cell ratio predict the efficacy of neoadjuvant chemotherapy and the prognosis of locally advanced gastric cancer patients treated with the oxaliplatin and capecitabine regimen. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7061-7075.	1.0	14
40	Solute carriers as potential oncodrivers or suppressors: their key functions in malignant tumor formation. <i>Drug Discovery Today</i> , 2021, 26, 1689-1701.	3.2	14
41	The Impact of Mismatch Repair Status on Prognosis of Patients With Gastric Cancer: A Multicenter Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 712760.	1.3	14
42	An integrated bioinformatic investigation of mitochondrial solute carrier family 25 (SLC25) in colon cancer followed by preliminary validation of member 5 (SLC25A5) in tumorigenesis. <i>Cell Death and Disease</i> , 2022, 13, 237.	2.7	14
43	The role of oxaliplatin in the adjuvant setting of different Lauren's type of gastric adenocarcinoma after D2 gastrectomy: a real-world study. <i>Gastric Cancer</i> , 2019, 22, 587-597.	2.7	13
44	ANGPTL6-mediated angiogenesis promotes alpha fetoprotein-producing gastric cancer progression. <i>Pathology Research and Practice</i> , 2019, 215, 152454.	1.0	12
45	A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab-based therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 287-295.	1.2	12
46	Benefits of multi-disciplinary treatment strategy on survival of patients with colorectal cancer liver metastasis. <i>Clinical and Translational Medicine</i> , 2020, 10, e121.	1.7	12
47	Bazedoxifene Attenuates Abdominal Aortic Aneurysm Formation via Downregulation of Interleukin-6/Glycoprotein 130/Signal Transducer and Activator of Transcription 3 Signaling Pathway in Apolipoprotein E Knockout Mice. <i>Frontiers in Pharmacology</i> , 2020, 11, 392.	1.6	12
48	Intra-tumor metabolic heterogeneity of gastric cancer on 18F-FDG PETCT indicates patient survival outcomes. <i>Clinical and Experimental Medicine</i> , 2021, 21, 129-138.	1.9	12
49	Hepatoid Adenocarcinoma of Stomach: Emphasis on the Clinical Relationship with Alpha-Fetoprotein-Positive Gastric Cancer. <i>BioMed Research International</i> , 2019, 2019, 1-9.	0.9	11
50	Identification of a Novel EHBP1-MET Fusion in an Intrahepatic Cholangiocarcinoma Responding to Crizotinib. <i>Oncologist</i> , 2020, 25, 1005-1008.	1.9	11
51	Growth-suppressive activity of raloxifene on liver cancer cells by targeting IL-6/GP130 signaling. <i>Oncotarget</i> , 2017, 8, 33683-33693.	0.8	11
52	Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 145-152.	1.1	10
53	Prostate-derived ETS factor improves prognosis and represses proliferation and invasion in hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 52488-52500.	0.8	10
54	Systemic chemotherapy as a main strategy for liver metastases from gastric cancer. <i>Clinical and Translational Oncology</i> , 2015, 17, 888-894.	1.2	9

#	ARTICLE	IF	CITATIONS
55	Impact of HER2 expression on outcome in gastric cancer patients with liver metastasis. <i>Clinical and Translational Oncology</i> , 2017, 19, 197-203.	1.2	9
56	<p>Outcomes of gastrectomy following upfront chemotherapy in advanced gastric cancer patients with a single noncurable factor: a cohort study</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 2007-2013.	0.9	8
57	A 16â€mRNA signature optimizes recurrenceâ€free survival prediction of Stages II and III gastric cancer. <i>Journal of Cellular Physiology</i> , 2020, 235, 5777-5786.	2.0	8
58	Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX). <i>Oncotarget</i> , 2016, 7, 76298-76307.	0.8	8
59	Stem cell programs are retained in human leukemic lymphoblasts. <i>Oncogene</i> , 2015, 34, 2083-2093.	2.6	7
60	IntegrinB5 upregulated by HER2 in gastric cancer: a promising biomarker for liver metastasis. <i>Annals of Translational Medicine</i> , 2020, 8, 451-451.	0.7	7
61	Volumetric parameters on 18F-FDG PET/CT predict the survival of patients with gastric cancer associated with their expression status of c-MET. <i>BMC Cancer</i> , 2019, 19, 790.	1.1	6
62	<p>Benefit of adjuvant chemoradiotherapy in patients with pathological stage III gastric cancer</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 6029-6041.	0.9	6
63	The value of dynamic contrast enhanced ultrasound (DCE-US) in monitoring treatment effect of high-intensity focused ultrasound (HIFU) in locally advanced pancreatic cancer (LAPC). <i>Clinical Hemorheology and Microcirculation</i> , 2021, 77, 323-333.	0.9	6
64	has prognostic value in colorectal cancer and represses Warburg effect and cell proliferation via Wnt signaling. <i>American Journal of Cancer Research</i> , 2020, 10, 1548-1567.	1.4	6
65	Identification of key genes involved in tumor immune cell infiltration and cetuximab resistance in colorectal cancer. <i>Cancer Cell International</i> , 2021, 21, 135.	1.8	5
66	Identification of a metabolic signature to predict overall survival for colorectal cancer. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 1078-1087.	0.6	5
67	The prognostic value of global myocardium strain by CMR-feature tracking in immune checkpoint inhibitorâ€associated myocarditis. <i>European Radiology</i> , 2022, 32, 7657-7667.	2.3	5
68	<p>Prognosis of Adjuvant SOX vs XELOX Chemotherapy for Gastric Cancer After D2 Gastrectomy in Chinese Patients</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 10091-10101.	0.9	4
69	Treatment strategy for myocarditis in patients using immune checkpoint inhibitors or combined anti-vascular endothelial growth factor therapy by clinical severity. <i>European Journal of Cancer</i> , 2021, 157, 10-20.	1.3	4
70	Treatment-related adverse events as predictive biomarkers of efficacy in patients with advanced neuroendocrine tumors treated with surufatinib: results from two phase III studies. <i>ESMO Open</i> , 2022, 7, 100453.	2.0	4
71	Predictive value of combining the SYNTAX score with reactive hyperemia index in patients with acute coronary syndrome undergoing percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, E130-E139.	0.7	3
72	Low-dosed docetaxel showed equivalent efficacy but improved tolerability compared with oxaliplatin in the S-1-based first-line chemotherapy regimen for metastatic or recurrent gastric adenocarcinoma. <i>Medical Oncology</i> , 2015, 32, 230.	1.2	1

#	ARTICLE	IF	CITATIONS
73	Subgroup Analysis by Liver Metastasis in the FRESKO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal Cancer. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4439-4450.	1.0	1
74	Phase I study of adjuvant chemotherapy with nab-paclitaxel and S1 for stage III Lauren's diffuse-type gastric cancer after D2 resection (NORDICA study). <i>Cancer Medicine</i> , 0, .	1.3	1
75	ASSA14-03-22...Lack of association between PON1 gene polymorphisms and high platelet reactivity in patients undergoing selective coronary stent placement in Chinese Han population. <i>Heart</i> , 2015, 101, A16.1-A16.	1.2	0
76	ASSA14-03-18...Contribution of Homeostatic Chemokines CCL19 and CCL21 and their Receptor CCR7 to Coronary Artery Disease. <i>Heart</i> , 2015, 101, A14.2-A14.	1.2	0
77	ASSA14-03-21...Polymorphisms of PON1 gene are associated with coronary artery disease. <i>Heart</i> , 2015, 101, A15.2-A15.	1.2	0
78	Trastuzumab plus docetaxel and capecitabine as a first-line treatment for HER2-positive advanced gastric or gastroesophageal junction cancer: a phase II, multicenter, open-label, single-arm study. <i>American Journal of Cancer Research</i> , 2020, 10, 3037-3046.	1.4	0
79	Changes in phagocytosis and expression of microglial cells in craniocerebral injury mice models. <i>Journal of Biological Regulators and Homeostatic Agents</i> , 2016, 30, 517-21.	0.7	0